Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Does tenofovir influence efavirenz pharmacokinetics?

Antiviral therapy - 1 Jan 2007

Rotger Margalida, Colombo Sara, Furrer Hansjakob, Décosterd Laurent, Buclin Thierry, Telenti Amalio

Abstract excerpt

INTRODUCTION: A recent report described a possible interaction between tenofovir (TFV) and efavirenz (EFV). Patients developed neuropsychiatric manifestations upon introduction of TFV on a stable EFV-containing regimen. We evaluated the possibility of a pharmacokinetic interaction between TFV and EFV by assessing cross-sectional and longitudinal data in 169 individuals receiving EFV. RESULTS: EFV plasma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Benzoxazines
Share to Cyclopropanes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2B6

Share to Organophosphonates

Share to Oxidoreductases, N-Demethylating

Share to Switzerland

Share to Tenofovir

Source

Identifiers

PMID: 17503755

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Does tenofovir influence efavirenz pharmacokinetics?PMID 17503755Read ↗

Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection.Semantic proximity Read ↗

Efavirenz and the CNS: what we already know and questions that need to be answered.Semantic proximity Read ↗

Assessment of the inter-individual variation observed between patients receiving HIV antiretroviral therapySemantic proximity Read ↗

Efavirenz in the therapy of HIV infectionSemantic proximity Read ↗

Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).Semantic proximity Read ↗

Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines.Semantic proximity Read ↗

Population Approach to Efavirenz Therapy.Semantic proximity Read ↗

Efavirenz intoxication due to a new CYP2B6 constellation.Semantic proximity Read ↗

Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria.Semantic proximity Read ↗

Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?Semantic proximity Read ↗

Pharmacogenetics of Tenofovir TreatmentSemantic proximity Read ↗

Plasma and Intracellular Population Pharmacokinetic Analysis of Tenofovir in HIV-1-Infected PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.